Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Clinical Trial ID NCT03779191

Rank	Title	Journal	Year	PubWeight™‹?›
1	Global cancer statistics, 2012.	CA Cancer J Clin	2015	53.52
2	Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.	Nature	2007	37.09
3	EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.	N Engl J Med	2010	8.59
4	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.	Clin Cancer Res	2012	6.23
5	EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.	J Thorac Oncol	2008	4.90
6	Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1.	Blood	1997	2.50
7	[National consensus of diagnosis and treatment of non-small cell lung cancer].	Rev Invest Clin	2013	2.04
8	One hundred years of lung cancer.	Am J Respir Crit Care Med	2005	1.90
9	Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.	Oncologist	2012	1.88